Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3882190 | 0.90 | GPR119 (0.40) | RENMAPT | |
| SCHEMBL2852273 | 0.89 | REN (0.40) | RENRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL2852276 | 0.89 | REN (0.40) | RENRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL2844217 | 0.87 | REN (0.51) | RENRXRB | |
| SCHEMBL2846462 | 0.87 | REN (0.51) | RENRXRB | |
| SCHEMBL2844219 | 0.87 | REN (0.51) | RENRXRB | |
| SCHEMBL2844214 | 0.87 | REN (0.51) | RENRXRB | |
| SCHEMBL4292202 | 0.87 | REN (0.51) | RENRXRB | |
| SCHEMBL2846467 | 0.87 | REN (0.51) | RENRXRB | |
| SCHEMBL2846454 | 0.87 | REN (0.60) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | REN 2/4885HSD17B10 1027/4885LMNA 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.